acitretin has been researched along with Hypertrophy in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Aung, PP; Curry, JL; Duke, TC; Glitza Oliva, IC; Ledesma, DA; Marques-Piubelli, ML; Nagarajan, P; Nelson, KC; Prieto, VG; Tetzlaff, MT; Torres-Cabala, CA; Wistuba, II | 1 |
Butler, DF; Eduardo, C; Sutton, L | 1 |
Alamri, A; Alsenaid, A; Ruzicka, T; Wolf, R | 1 |
Al-Mutairi, N; Nour-Eldin, O; Rijhwani, M | 1 |
4 other study(ies) available for acitretin and Hypertrophy
Article | Year |
---|---|
Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Topics: Acitretin; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dermatitis; Drug Eruptions; Drug Therapy, Combination; Exportin 1 Protein; Female; Fluocinonide; Glucocorticoids; Humans; Hypertrophy; Immune Checkpoint Inhibitors; Karyopherins; Keratolytic Agents; Lichenoid Eruptions; Melanoma; Programmed Cell Death 1 Receptor; Receptors, Cytoplasmic and Nuclear; Treatment Outcome; Triamcinolone | 2020 |
Diffuse lichenplanopilaris and multiple squamous neoplasms.
Topics: Acitretin; Aged; Carcinoma, Squamous Cell; Dermatitis; Female; Humans; Hypertrophy; Keratoacanthoma; Keratolytic Agents; Lichen Planus; Skin Diseases; Skin Neoplasms | 2015 |
Hypertrophic lichen planus - successful treatment with acitretin.
Topics: Acitretin; Administration, Oral; Aged; Biopsy; Dermatologic Agents; Humans; Hypertrophy; Lichen Planus; Male; Middle Aged; Remission Induction; Skin; Treatment Outcome | 2016 |
Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy.
Topics: Acitretin; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Hypertrophy; Immunohistochemistry; Keratolytic Agents; Lupus Erythematosus, Discoid; Male; Severity of Illness Index; Treatment Outcome | 2005 |